Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025PRNewsWire • 11/06/25
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)PRNewsWire • 09/30/25
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum DepressionPRNewsWire • 06/26/25
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025PRNewsWire • 06/23/25
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154PRNewsWire • 03/26/25
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated CirrhosisPRNewsWire • 12/17/24
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut SessionPRNewsWire • 11/18/24
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024PRNewsWire • 11/07/24
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South KoreaPRNewsWire • 10/31/24
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) CountriesPRNewsWire • 10/08/24
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024PRNewsWire • 10/02/24